Prescription drug monitoring programs use mandates and prescription stimulant and depressant quantities.
Health policy/regulation
Observational data/quasi-experiment
Substance abuse
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
11 07 2023
11 07 2023
Historique:
received:
09
02
2023
accepted:
06
07
2023
medline:
13
7
2023
pubmed:
12
7
2023
entrez:
11
7
2023
Statut:
epublish
Résumé
While the mandate to check patients' prescription history in Prescription Drug Monitoring Program (PDMP) database before prescribing/dispensing controlled drugs has been shown to be an important tool to curb opioid abuse, less is known about whether the mandate can reduce the misuse of other commonly abused prescription drugs. We examined whether PDMP use mandates were associated with changes in prescription stimulant and depressant quantities. Using data from Automated Reports and Consolidate Ordering System (ARCOS), we employed difference-in-differences design to estimate the association between PDMP use mandates and prescription stimulant and depressant quantities in 50 U.S. states and the District of Columbia from 2006 to 2020. Limited PDMP use mandate was specific only to opioids or benzodiazepines. Expansive PDMP use mandate was non-specific to opioid or benzodiazepine and required prescribers/dispensers to check PDMP when prescribing/dispensing targeted controlled substances in Schedule II-V. The main outcomes were population-adjusted prescription stimulant (amphetamine, methylphenidate, lisdexamfetamine) and depressant (amobarbital, butalbital, pentobarbital, secobarbital) quantities in grams. There was no evidence that limited PDMP use mandate was associated with a reduction in the prescription stimulant and depressant quantities. However, expansive PDMP use mandate that was non-specific to opioid or benzodiazepine and required prescribers/dispensers to check PDMP when prescribing/dispensing targeted controlled substances in Schedule II-V was associated with 6.2% (95% CI: -10.06%, -2.08%) decline in prescription amphetamine quantity. Expansive PDMP use mandate was associated with a decline in prescription amphetamine quantity. Limited PDMP use mandate did not appear to change prescription stimulant and depressant quantities.
Sections du résumé
BACKGROUND
While the mandate to check patients' prescription history in Prescription Drug Monitoring Program (PDMP) database before prescribing/dispensing controlled drugs has been shown to be an important tool to curb opioid abuse, less is known about whether the mandate can reduce the misuse of other commonly abused prescription drugs. We examined whether PDMP use mandates were associated with changes in prescription stimulant and depressant quantities.
METHODS
Using data from Automated Reports and Consolidate Ordering System (ARCOS), we employed difference-in-differences design to estimate the association between PDMP use mandates and prescription stimulant and depressant quantities in 50 U.S. states and the District of Columbia from 2006 to 2020. Limited PDMP use mandate was specific only to opioids or benzodiazepines. Expansive PDMP use mandate was non-specific to opioid or benzodiazepine and required prescribers/dispensers to check PDMP when prescribing/dispensing targeted controlled substances in Schedule II-V. The main outcomes were population-adjusted prescription stimulant (amphetamine, methylphenidate, lisdexamfetamine) and depressant (amobarbital, butalbital, pentobarbital, secobarbital) quantities in grams.
RESULTS
There was no evidence that limited PDMP use mandate was associated with a reduction in the prescription stimulant and depressant quantities. However, expansive PDMP use mandate that was non-specific to opioid or benzodiazepine and required prescribers/dispensers to check PDMP when prescribing/dispensing targeted controlled substances in Schedule II-V was associated with 6.2% (95% CI: -10.06%, -2.08%) decline in prescription amphetamine quantity.
CONCLUSION
Expansive PDMP use mandate was associated with a decline in prescription amphetamine quantity. Limited PDMP use mandate did not appear to change prescription stimulant and depressant quantities.
Identifiants
pubmed: 37434122
doi: 10.1186/s12889-023-16256-9
pii: 10.1186/s12889-023-16256-9
pmc: PMC10334646
doi:
Substances chimiques
Analgesics, Opioid
0
Controlled Substances
0
Amphetamine
CK833KGX7E
Benzodiazepines
12794-10-4
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1326Subventions
Organisme : NIDA NIH HHS
ID : R01DA042290
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA049730
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Addiction. 1994 Oct;89(10):1299-308
pubmed: 7804091
Drug Alcohol Depend. 2022 Feb 1;231:109232
pubmed: 35007956
J Policy Anal Manage. 2019;38(1):181-209
pubmed: 30572414
Lancet Reg Health Am. 2022 Jan 24;10:100190
pubmed: 36777690
Subst Abus. 2021;42(3):294-301
pubmed: 31697195
N Engl J Med. 2016 Jul 7;375(1):44-53
pubmed: 27332619
Drug Alcohol Depend. 2017 Sep 1;178:348-354
pubmed: 28692945
Health Aff (Millwood). 2016 Jul 1;35(7):1324-32
pubmed: 27335101
Addiction. 2017 Oct;112(10):1773-1783
pubmed: 28009931
Addiction. 2020 May;115(5):946-958
pubmed: 31912625
Health Aff (Millwood). 2019 Sep;38(9):1550-1556
pubmed: 31479368
Drug Alcohol Depend. 2014 Dec 1;145:34-47
pubmed: 25454406
JAMA. 2021 Jul 20;326(3):274-276
pubmed: 34125882
BMJ. 1996 Aug 17;313(7054):402
pubmed: 8761230
JAMA. 2008 Dec 10;300(22):2613-20
pubmed: 19066381
Am J Public Health. 2016 Apr;106(4):686-8
pubmed: 26890165
J Health Econ. 2021 Jan;75:102408
pubmed: 33316762
JAMA Oncol. 2020 Jul 1;6(7):1102-1103
pubmed: 32379277
Drug Alcohol Depend. 2018 Mar 1;184:26-32
pubmed: 29402676
Drug Alcohol Depend. 2018 Jul 1;188:169-174
pubmed: 29778769
Health Aff (Millwood). 2021 Mar;40(3):461-468
pubmed: 33646863
J Health Econ. 2021 Mar;76:102397
pubmed: 33383263